Clovertex’s September 2025 Target of the Month is LGR5, in light of Genmab’s announcement that it wi...
After a bit of a break, we're back with our Hottest Social roundup. On the technical front, cryo-EM ...
Clovertex’s August 2025 Target of the Month is MC4R (melanocortin‑4 receptor). MC4R is a GPCR that p...
Clovertex’s June Target of the Month is KIT, highlighted by Sanofi’s acquisition of Blueprint Medici...
Clovertex’s May Target of the Month is B-Raf, a serine/threonine kinase that plays a central role in...
Bitter days for the industry, sweet days for cryo-EM. This month’s SBDD social pulse captures a stri...
Clovertex’s April 2025 Target of the Month is the neonatal Fc receptor (FcRn), following the U.S. FD...
April delivered no shortage of turbulence — but also a few genuine bright spots. Amid ongoing instab...
Clovertex’s March Target of the Month is GSPT1, a translation termination factor that plays a vital ...
This month, Cryo-EM provided new insights into the vitamin K enzyme, as well as channel and GPCR str...